Except from DoH press release below
full press release available at
http://tap.ukwebhost.eds.com/doh/Intpress.nsf/page/2002-0360?OpenDocument
Best wishes
David McDaid
LSE Health and Social Care
23rd August 2002
Eighth wave of NICE Work Programme goes out for consultation
New treatments for cancer, coronary heart disease, psoriasis and asthma are being considered for referral to the National Institute for Clinical Excellence (NICE).
NICE was set up in 1999 to help tackle the postcode lottery of prescribing - where treatments are available in some areas and not others. It should also speed up the uptake of clinically and cost effective new treatments by issuing clear, evidence-based guidance to the NHS on the use of drugs and treatments. Where NICE recommends a treatment, Primary Care Trusts and Health Authorities are under a legal obligation to provide funding in appropriate cases.
Stakeholders, including professional and patient groups and relevant manufacturers, have been asked to comment on the proposals by the end of September. If the proposed topics are confirmed following this consultation, they will form part of an 8th wave of appraisals and clinical guidelines to be referred to NICE later this year.
The treatments to be looked at as part of the consultation are:
1. Iressa for non-small cell lung cancer
2. Imatinib (Glivec) for gastro-intestinal stromal tumours
3. Dual chamber pacing in elderly patients
4. Xaliproden for motor neurone disease
5. Parent training programmes, for treatment and prevention of conduct disorder
6. Omalizumab (Xolair) for uncontrolled asthma
7. Corticosteroids in the treatment of asthma
8. Drotecogin (Xigris) and afelimomab (Segard) for severe sepsis
9. New treatments for moderate to severe psoriasis
10. Pimecrolimus (Elidel) for atopic dermatitis
11. Topical steroids in atopic eczema
Notes for editors
|